Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Experience with perindopril in normal volunteers.

B Waeber1, J Nussberger, L Perret

  • 1Division of Hypertension, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

Archives Des Maladies Du Coeur Et Des Vaisseaux
|May 1, 1989
PubMed
Summary

The novel angiotensin converting enzyme (ACE) inhibitor, perindopril, effectively reduces blood pressure responses in men. This long-acting ACE inhibitor is well-tolerated and effective in daily oral doses of 4 to 16 mg.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Triple-combination therapy in the treatment of hypertension: a review of the evidence.

Journal of human hypertension·2017
Same author

Archives of gynecology and obstetrics·2016
Same author

PP125. High mobility group box 1 protein (HMGB1): A pathogenic role in preeclampsia?

Pregnancy hypertension·2015
Same author

Physiological response to whole-body vibration in athletes and sedentary subjects.

Physiological research·2014
Same author

High mobility group box 1 protein (HMGB-1): a pathogenic role in preeclampsia?

Placenta·2014
Same author

[Hypertension. Effects of antihypertensive therapy on cognitive functions].

Revue medicale suisse·2013

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Angiotensin converting enzyme (ACE) inhibitors are crucial in managing cardiovascular conditions.
  • Perindopril is a new orally active ACE inhibitor with a long duration of action.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of perindopril in normotensive men.
  • To assess the pharmacokinetic and pharmacodynamic profile of perindopril.

Main Methods:

  • Administration of perindopril in doses ranging from 2 to 16 mg once daily for up to one week.
  • Measurement of plasma ACE activity, angiotensin I and II levels, aldosterone, and plasma renin activity.
  • Monitoring of blood pressure and heart rate.

Main Results:

Related Experiment Videos

  • Perindopril demonstrated dose-dependent inhibition of the pressor response to angiotensin I.
  • Peak ACE inhibition occurred 4-8 hours post-dose, with significant reduction lasting 24 hours.
  • Decreased levels of angiotensin II and aldosterone, with increased plasma renin activity and angiotensin I levels observed during peak inhibition.

    • Conclusions:

    • Perindopril is an effective and well-tolerated long-acting ACE inhibitor for oral administration.
    • Effective oral dosage for perindopril ranges from 4 to 16 mg.
    • No evidence of drug accumulation or significant changes in routine laboratory tests was observed.